{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T06:31:22Z","timestamp":1785825082923,"version":"3.56.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s40273-025-01580-2","type":"journal-article","created":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T13:37:09Z","timestamp":1768829829000},"page":"329-341","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Development of Cardiovascular Risk Equations in People with Overweight or Obesity and Established Cardiovascular Disease Without Diabetes Based on the SELECT Trial"],"prefix":"10.1007","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6431-8307","authenticated-orcid":false,"given":"Martin","family":"B\u00f8g","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders Bo","family":"Bojesen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Emerson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milana","family":"Ivkovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nia C.","family":"Jenkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"L\u00fcbker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Mamdani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Padgett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc","family":"Van Gaal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter E.","family":"Weeke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Michael","family":"Lincoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,19]]},"reference":[{"key":"1580_CR1","unstructured":"World Obesity Federation. World obesity atlas 2023. 2023. https:\/\/data.worldobesity.org\/publications\/?cat=19. Accessed 27 Dec 2025."},{"key":"1580_CR2","doi-asserted-by":"publisher","DOI":"10.1111\/obr.13112","volume":"22","author":"J Wilding","year":"2020","unstructured":"Wilding J, Jacob S. Cardiovascular outcome trials in obesity: a review. Obes Rev. 2020;22:e13112.","journal-title":"Obes Rev"},{"key":"1580_CR3","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.ahj.2020.07.008","volume":"229","author":"DH Ryan","year":"2020","unstructured":"Ryan DH, Lingvay I, Colhoun HM, et al. Semaglutide effects on cardiovascular outcomes in people with overweight or obesity (SELECT) rationale and design. Am Heart J. 2020;229:61\u20139.","journal-title":"Am Heart J"},{"issue":"17","key":"1580_CR4","doi-asserted-by":"publisher","first-page":"2218","DOI":"10.1093\/eurjpc\/zwac187","volume":"29","author":"F Lopez-Jimenez","year":"2022","unstructured":"Lopez-Jimenez F, Almahmeed W, Bays H, et al. Obesity and cardiovascular disease: mechanistic insights and management strategies: a joint position paper by the World Heart Federation and World Obesity Federation. Eur J Prev Cardiol. 2022;29(17):2218\u201337.","journal-title":"Eur J Prev Cardiol"},{"issue":"3","key":"1580_CR5","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1002\/osp4.495","volume":"7","author":"S Lopes","year":"2021","unstructured":"Lopes S, Meincke HH, Lamotte M, et al. A novel decision model to predict the impact of weight management interventions: the Core Obesity Model. Obes Sci Pract. 2021;7(3):269\u201380.","journal-title":"Obes Sci Pract"},{"issue":"7","key":"1580_CR6","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1002\/oby.24310","volume":"33","author":"MM Hoog","year":"2025","unstructured":"Hoog MM, Kan H, Deger KA, et al. Modeling potential cost-effectiveness of tirzepatide versus lifestyle modification for patients with overweight and obesity. Obesity. 2025;33(7):1297\u2013308.","journal-title":"Obesity"},{"issue":"10","key":"1580_CR7","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1007\/s40273-020-00941-3","volume":"38","author":"S Lopes","year":"2020","unstructured":"Lopes S, Johansen P, Lamotte M, et al. External validation of the core obesity model to assess the cost-effectiveness of weight management interventions. Pharmacoeconomics. 2020;38(10):1123\u201333.","journal-title":"Pharmacoeconomics"},{"issue":"24","key":"1580_CR8","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","volume":"389","author":"AM Lincoff","year":"2023","unstructured":"Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221\u201332.","journal-title":"N Engl J Med"},{"issue":"1","key":"1580_CR9","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1002\/oby.23621","volume":"31","author":"I Lingvay","year":"2023","unstructured":"Lingvay I, Brown-Frandsen K, Colhoun HM, et al. Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristics. Obesity. 2023;31(1):111\u201322.","journal-title":"Obesity"},{"issue":"20","key":"1580_CR10","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1016\/j.jacc.2012.01.044","volume":"59","author":"V Regnault","year":"2012","unstructured":"Regnault V, Thomas F, Safar ME, et al. Sex difference in cardiovascular risk: role of pulse pressure amplification. J Am Coll Cardiol. 2012;59(20):1771\u20137.","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"1580_CR11","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1161\/01.CIR.100.4.354","volume":"100","author":"SS Franklin","year":"1999","unstructured":"Franklin SS, Khan SA, Wong ND, et al. Is pulse pressure useful in predicting risk for coronary heart disease? The Framingham Heart Study. Circulation. 1999;100(4):354\u201360.","journal-title":"Circulation"},{"issue":"11","key":"1580_CR12","first-page":"e563","volume":"140","author":"DK Arnett","year":"2019","unstructured":"Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on clinical practice guidelines. Circulation. 2019;140(11):e563\u201395.","journal-title":"Circulation"},{"issue":"34","key":"1580_CR13","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","volume":"42","author":"FLJ Visseren","year":"2021","unstructured":"Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC guidelines on cardiovascular disease prevention in clinical practice: developed by the Task Force for cardiovascular Disease Prevention in Clinical Practice with representatives of the European Society of Cardiology and 12 medical societies with the special contribution of the European Association of Preventive Cardiology (EAPC). Eur Heart J. 2021;42(34):3227\u201337.","journal-title":"Eur Heart J"},{"key":"1580_CR14","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j2099","volume":"357","author":"J Hippisley-Cox","year":"2017","unstructured":"Hippisley-Cox J, Coupland C, Brindle P. Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study. BMJ. 2017;357:j2099.","journal-title":"BMJ"},{"issue":"2 Pt 1","key":"1580_CR15","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/S0002-8703(00)90236-9","volume":"139","author":"RB D'Agostino","year":"2000","unstructured":"D\u2019Agostino RB, Russell MW, Huse DM, et al. Primary and subsequent coronary risk appraisal: new results from the Framingham study. Am Heart J. 2000;139(2 Pt 1):272\u201381.","journal-title":"Am Heart J"},{"key":"1580_CR16","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.ijcard.2020.09.053","volume":"325","author":"CCV Klooster","year":"2021","unstructured":"Klooster CCV, Bhatt DL, Steg PG, et al. Predicting 10-year risk of recurrent cardiovascular events andcardiovascular interventions in patients with established cardiovascular disease: results from UCC-SMART and REACH. Int J Cardiol. 2021;325:140\u20138.","journal-title":"Int J Cardiol"},{"issue":"10","key":"1580_CR17","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.2337\/dc08-0662","volume":"31","author":"J Cederholm","year":"2008","unstructured":"Cederholm J, Eeg-Olofsson K, Eliasson B, et al. Risk prediction of cardiovascular disease in type 2 diabetes: a risk equation from the Swedish National Diabetes Register. Diabetes Care. 2008;31(10):2038\u201343.","journal-title":"Diabetes Care"},{"issue":"9","key":"1580_CR18","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1007\/s00125-013-2940-y","volume":"56","author":"AJ Hayes","year":"2013","unstructured":"Hayes AJ, Leal J, Gray AM, et al. UKPDS outcomes model 2: a new version of a model to simulate lifetime health outcomes of patients with type 2 diabetes mellitus using data from the 30 year United Kingdom Prospective Diabetes Study: UKPDS 82. Diabetologia. 2013;56(9):1925\u201333.","journal-title":"Diabetologia"},{"issue":"9","key":"1580_CR19","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.121.022198","volume":"11","author":"DL Steen","year":"2022","unstructured":"Steen DL, Khan I, Andrade K, et al. Event rates and risk factors for recurrent cardiovascular events and mortality in a contemporary post acute coronary syndrome population representing 239 234 patients during 2005 to 2018 in the United States. J Am Heart Assoc. 2022;11(9):e022198.","journal-title":"J Am Heart Assoc"},{"issue":"12","key":"1580_CR20","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1136\/heartjnl-2013-303640","volume":"99","author":"JA Dorresteijn","year":"2013","unstructured":"Dorresteijn JA, Visseren FL, Wassink AM, et al. Development and validation of a prediction rule for recurrent vascular events based on a cohort study of patients with arterial disease: the SMART risk score. Heart. 2013;99(12):866\u201372.","journal-title":"Heart"},{"key":"1580_CR21","doi-asserted-by":"publisher","DOI":"10.1155\/2024\/4133365","volume":"2024","author":"I Talha","year":"2024","unstructured":"Talha I, Elkhoudri N, Hilali A. Major limitations of cardiovascular risk scores. Cardiovasc Ther. 2024;2024:4133365.","journal-title":"Cardiovasc Ther"},{"issue":"9","key":"1580_CR22","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/j.jval.2020.04.1832","volume":"23","author":"L Si","year":"2020","unstructured":"Si L, Willis MS, Asseburg C, et al. Evaluating the ability of economic models of diabetes to simulate new cardiovascular outcomes trials: a report on the Ninth Mount Hood Diabetes Challenge. Value Health. 2020;23(9):1163\u201370.","journal-title":"Value Health"},{"issue":"1","key":"1580_CR23","doi-asserted-by":"publisher","first-page":"14","DOI":"10.2337\/dci17-0057","volume":"41","author":"WT Cefalu","year":"2017","unstructured":"Cefalu WT, Kaul S, Gerstein HC, et al. Cardiovascular outcomes trials in type 2 diabetes: where do we go from here? Reflections from a Diabetes Care Editors\u2019 Expert Forum. Diabetes Care. 2017;41(1):14\u201331.","journal-title":"Diabetes Care"},{"issue":"5","key":"1580_CR24","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1007\/s13300-019-00681-4","volume":"10","author":"M Willis","year":"2019","unstructured":"Willis M, Asseburg C, Nilsson A, et al. Challenges and opportunities associated with incorporating new evidence of drug-mediated cardioprotection in the economic modeling of type 2 diabetes: a literature review. Diabetes Ther. 2019;10(5):1753\u201369.","journal-title":"Diabetes Ther"},{"issue":"10516","key":"1580_CR25","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.1016\/S0140-6736(25)01375-3","volume":"406","author":"J Deanfield","year":"2025","unstructured":"Deanfield J, Lincoff AM, Kahn SE, et al. Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trial. Lancet. 2025;406(10516):2257\u201368.","journal-title":"Lancet"},{"key":"1580_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2017.08.2079","volume":"20","author":"P McEwan","year":"2017","unstructured":"McEwan P, Chubb B, Bennett Wilton H. Modelling cardiovascular outcomes in type 2 diabetes in the era of cardiovascular outcomes trials. Value Health. 2017;20:A747.","journal-title":"Value Health"},{"issue":"18","key":"1580_CR27","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.1093\/eurjpc\/zwaa098","volume":"28","author":"KK Poppe","year":"2022","unstructured":"Poppe KK, Wells S, Jackson R, et al. Predicting cardiovascular disease risk across the atherosclerotic disease continuum. Eur J Prev Cardiol. 2022;28(18):2010\u20137.","journal-title":"Eur J Prev Cardiol"},{"issue":"2","key":"1580_CR28","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1093\/eurjpc\/zwad314","volume":"31","author":"A Holt","year":"2024","unstructured":"Holt A, Batinica B, Liang J, et al. Development and validation of cardiovascular risk prediction equations in 76 000 people with known cardiovascular disease. Eur J Prev Cardiol. 2024;31(2):218\u201327.","journal-title":"Eur J Prev Cardiol"},{"issue":"2","key":"1580_CR29","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.jval.2018.08.003","volume":"22","author":"MB Betts","year":"2019","unstructured":"Betts MB, Milev S, Hoog M, et al. Comparison of recommendations and use of cardiovascular risk equations by health technology assessment agencies and clinical guidelines. Value Health. 2019;22(2):210\u20139.","journal-title":"Value Health"},{"issue":"7","key":"1580_CR30","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1007\/s00592-023-02045-8","volume":"60","author":"X Li","year":"2023","unstructured":"Li X, Li F, Wang J, et al. Prediction of complications in health economic models of type 2 diabetes: a review of methods used. Acta Diabetol. 2023;60(7):861\u201379.","journal-title":"Acta Diabetol"},{"issue":"14","key":"1580_CR31","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1001\/jama.2017.12126","volume":"318","author":"AC Alba","year":"2017","unstructured":"Alba AC, Agoritsas T, Walsh M, et al. Discrimination and calibration of clinical prediction models: users\u2019 guides to the medical literature. JAMA. 2017;318(14):1377\u201384.","journal-title":"JAMA"},{"issue":"7","key":"1580_CR32","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1007\/s00592-022-01891-2","volume":"59","author":"S Emamipour","year":"2022","unstructured":"Emamipour S, Pagano E, Di Cuonzo D, et al. The transferability and validity of a population-level simulation model for the economic evaluation of interventions in diabetes: the MICADO model. Acta Diabetol. 2022;59(7):949\u201357.","journal-title":"Acta Diabetol"}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-025-01580-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40273-025-01580-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-025-01580-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T13:30:00Z","timestamp":1771421400000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40273-025-01580-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,19]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["1580"],"URL":"https:\/\/doi.org\/10.1007\/s40273-025-01580-2","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"value":"1170-7690","type":"print"},{"value":"1179-2027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,19]]},"assertion":[{"value":"6 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Martin B\u00f8g, Anders Bo Bojesen, Milana Ivkovic, Christopher L\u00fcbker and Peter E. Weeke are employees of Novo Nordisk. Nia C. Jenkins and Thomas Padgett are employees of Health Economics and Outcomes Research Ltd. Health Economics and Outcomes Research Ltd. received fees from Novo Nordisk in relation to this study. Scott Emerson has received consulting honoraria from Amylyx, AstraZeneca, Avillion, Ayala, Bayer, BeiGene, Boehringer Ingelheim, 89 Bio, BioAge, BioAtla, Bristol Meyer Squibb, BridgeBio, Daiichi Sankyo, Denovo, Fore Therapeutics, GlaxoSmithKline, Inovio, Insmed, Ipsen, Karuna, Lilly, Lundbeck, Mirati, Moderna, Novartis, Novavax, Novo Nordisk, NSABP, Pfizer, Principia, Reata, Rebiotx, Roche, Sanofi, SOLVD, Sutro Biopharma and TG Therapeutics. Muhammad Mamdani has received grant funding from Roche, honoraria for speaking engagements and one-time advisory boards from Takeda and Baxter, and is an advisor to Signal 1 and Mutual Health. A. Michael Lincoff has received research grants paid to his institution from AbbVie Inc., AstraZeneca, CSL Behring, Eli Lilly and Company, Esperion Therapeutics, Inc. and Novartis and has served as a consultant for Akebia Therapeutics Inc., Alnylam Pharmaceuticals Inc., Ardelyx, Canary Cure, Eli Lilly and Company, FibroGen, GlaxoSmithKline, Intarcia, Medtronic Vascular, Inc., Novartis Pharmaceuticals Corporation, Novo Nordisk, Provention Bio, Entity and ReCor Medica. Luc Van Gaal is a member of the speakers bureau and\/or advisory board for Bayer Pharma, Boehringer Ingelheim, Currax Pharma, Daiichi-Sankyo, Eli Lilly & Co., Nestl\u00e9 Health Science, Novo Nordisk and Regeneron Pharma.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The CPRD Independent Scientific Advisory Committee for Medicines & Healthcare products Regulatory Agency database research granted ethics approval (protocol number 22_002360).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The datasets generated and\/or analysed during the current study are available from the corresponding author on reasonable request.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"MB, ABB and MI conceptualised and designed the study. NJ and TP were responsible for the data analysis. All authors contributed to interpretation of the results, review of the manuscript and approval of the final manuscript for publication.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}